KMDA Kamada Ltd.

NewsSee all news

1. 02 December 2019 Kamada Enters into Partnership with Alvotech for Commercialization of Six Biosimilar Products in Israel

   REHOVOT, Israel, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize

2. 13 November 2019 Kamada Reports Financial Results for Third Quarter and First Nine Months of 2019

   Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018.As a Reminder, Kamada's

3. 07 November 2019 Kamada to Report Third Quarter 2019 Financial Results and Host Conference Call on November 13

   REHOVOT, Israel, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and

4. 24 September 2019 Kamada to Present Corporate Overview at the 2019 Cantor Global Healthcare Conference

   REHOVOT, Israel, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a

5. 04 September 2019 Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda

   Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada